Generics Bulletin Editor’s Picks For Q1 2022
Highlights Across The Off-Patent Sector From January To March 2022
Executive Summary
Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.
You may also be interested in...
Fresenius Kabi Takes Control Of mAbxience To Bolster Biosimilars
Fresenius Kabi has made a major move to bolster its biosimilars business by acquiring a majority 55% stake in mAbxience, with the purchase price comprising €495m upfront as well as subsequent milestone payments. The deal offers Fresenius not only enhanced biosimilars capabilities but also access to the expanding biologics CDMO market.
AAM Calls Out Threat Of Consolidation Among Purchasers
Drug buying groups and pharmacy benefit managers are leaving generic drug producers unable to compete even when they have viable products due to concentration of buyer power, the Association for Accessible Medicines has highlighted.
Stampa Urges Investment In European Manufacturing
Fresh from being named as the new president of Medicines for Europe, Medichem CEO Elisabeth Stampa sets out the association’s priorities around investment in European manufacturing, as well as identifying key obstacles that must be overcome to create a sustainable environment for off-patent medicines, in an exclusive interview with Generics Bulletin.